Ceralifimod

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCeralifimod
Drug Alias Nameceralifimodum瑟雷莫德赛拉莫德ceralifimodONO-4641 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 agonistsSphingosine 1-phosphate receptor 5 agonists
TargetsSphingosine 1-Phosphate Receptor 1Sphingosine 1-phosphate receptor 5
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmd Serono IncMerck KGaA, Darmstadt, GermanyOno Pharmaceutical Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A